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In the present study, the effect of Fumigaclavine C, a fungal metabolite, on murine experimental colitis
induced by dextran sulfate sodium (DSS) and its possible mechanism were examined in vivo and vitro.
Oral administration of Fumigaclavine C dose-dependently attenuated the loss of body weight and
shortening of colon length induced by DSS. The disease activity index, histopathologic scores of musco
was also signiﬁcantly reduced by Fumigaclavine C treatment. Protein and mRNA levels of DSS-induced
pro-inﬂammatory cytokines in colon, including TNF-a, IL-1b and IL-17A, were markedly suppressed by
Fumigaclavine C. At the same time, decreased activation of caspase-1 in peritoneal macrophages was
detected in Fumigaclavine C -treated mice which suggested that the NLRP3 inﬂammasome activationwas
suppressed. Furthermore, in the LPS plus ATP cell model, we found that Fumigaclavine C dose-dependent
inhibited IL-1b release and caspase-1 activation. Taken together, our results demonstrate the ability of
Fumigaclavine C to inhibit NLRP3 inﬂammasome activation and give some evidence for its potential use
in the treatment of inﬂammatory bowel diseases.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Ulcerative colitis, characterized by chronic, relapsing and
remitting inﬂammation, not only impairs patients' quality of life,
but also increases the risk of colon cancer (1,2). A lot of evidence has
shown that the risk of colorectal cancer development in patients
with IBD is much higher than that in the general population. The
pathogenesis of ulcerative colitis is complicated and may involve
genetic, environmental and immunological factors (3). It is sug-
gested that dysfunctional of the epithelial barrier, provoked by
physical/chemical damage or genetic mutations, will caused inap-
propriate responses to microbiota or related products thus result-
ing in chronic inﬂammation (4,5). To investigate this disease in
mice, a chemical-induced model of acute colonic inﬂammation has
been introduced by oral administration of dextran sulfate sodium
(DSS) and characterized by a general inﬂammatory process5.
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d/4.0/).associated with weight loss and histopathologic features that
mimic some clinical demonstrations of ulcerative colitis. By oral
administration of DSS, mice develop an inﬂammatory condition in
the intestine associated with clinical symptoms (diarrhea,
abdominal pain, and weight loss), histopathological features and
changes in cytokine proﬁle, which resembles ulcerative colitis in
human (6,7). Here we use this model to search for potential ther-
apeutic compounds for ulcerative colitis.
Fumigaclavine C, an alkaloidal metabolite, was isolated from
the culture of Cephalosporium sp. IFB-018, an endophytic fun-
gus from the rhizoma of a salinity-tolerant medicinal plant
Imperata cylindrical by a column chromatography fraction from
the chloroformemethanol (1:1) extract and was identiﬁed by a
combination of spectroscopic methods as reported previously
by us (8). Our previous study has reported its immunosup-
pressive activity against Con A-induced hepatitis and TNBS-
induced colitis in mice via down regulating Th1 cytokine pro-
duction (9,10), which suggests that this compound may have a
characteristic to inhibit the T-cell mediated immune response.
In this study, we tried to test whether Fumigaclavine C can be
beneﬁt for ulcerative colitis treatment and search for its
possible mechanism.nese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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2.1. Mice
Six-to eight-week-old female C57BL/6 mice were purchased
fromModel Animal Genetics Research Center of Nanjing University
(Nanjing, China). Animal welfare and experimental procedures
were carried out strictly in accordance with the Guide for the Care
and Use of Laboratory Animals (National Institutes of Health, the
United States) and the related ethical regulations of our university.
All efforts were made to minimize animals' suffering and to reduce
the number of animals used.
2.2. Reagents
Fumigaclavine C (more than 90% of purity, isolated and identi-
ﬁed as reported. Phorbol myristate acetate (PMA), lipopolysaccha-
ride (LPS) and adenosine triphosphate (ATP) were purchased from
SigmaeAldrich (St. Louis, MO). Dextran sulfate sodium (DSS,
36e50 kDa) was bought from MP Biomedical (Aurora, OH). RPMI-
1640 and Fetal bowel serum were purchased from Life technology
(Carlsbad, CA). Anti-NLRP3 and anti-caspase-1 were purchased
from Epitomics (Burlingame, CA). Anti-ASC and anti-p-p65 was
purchased from Santa Cruz (Santa Cruz, CA). Anti-p-STAT1 and
anti-p-STAT3 were bought from Cell Signaling Technology.
Caspase-1 Assay Kit was bought from Beyotime (Nantong, China).
ELISA kits for murine TNF-a, IL-1b, IL-17A and human IL-1b were
purchased from Dakewe Biotech Co. Ltd (Beijing, China). All other
chemicals were purchased from SigmaeAldrich (St. Louis, MO).
2.3. Cell culture
Human THP-1 cells were purchased from Shanghai Institute of
Cell Biology (Shanghai, China) and maintained in RPMI 1640 me-
dium, supplemented with 100 U/ml of penicillin, 100 mg/ml of
streptomycin and 10% fetal calf serum under a humidiﬁed 5% (v/v)
CO2 atmosphere at 37 C. Peritoneal macrophages were obtained
from the peritoneal cavity by injection of PBS. Cells were washed
twice in PBS and suspended in RPMI-1640 medium containing 10%
FCS, 10,000 U/ml penicillin and 10 mg/ml streptomycin. The mac-
rophages suspended in culture medium were cultured in 24-well
microplates for 40 min at 37 C in a moist atmosphere of 5% CO2.
Non adherent cells were removed by washing the plate twice with
PBS. The adherent macrophages were used for experiments.
2.4. Induction of colitis and treatment
Colitis was induced in C57BL/6 mice with 2.5% DSS (molecular
weight 36e50 kDa) dissolved in drinking water (days 1e7). Normal
mice were given water. Vehicle control (PBS), Fumigaclavine C (3,
10, 30 mg/kg) and Cyclosporine A (CsA) (20 mg/kg) were given
orally from day 1 to day 10, respectively.
2.5. Clinical scoring and histological analysis
Bodyweight, stool consistency and the presence of gross blood in
feces and at the anus were observed everyday. The disease activity
index (DAI) was calculated by assigning well-established and vali-
dated scores. Brieﬂy, the following parameters were used for
calculation: a) diarrhea (0 points¼ normal, 2 points¼ loose stools, 4
points¼watery diarrhea); b) hematochezia (0 points¼ no bleeding,
2, slight bleeding, 4 points, gross bleeding) (11). At day 10 following
induction of colitis, animals were sacriﬁced, the colon was removed
and pieces of colonic tissue were used for ex vivo analysis. For his-
tological analysis, part of the colon was ﬁxed in 10% bufferedformalin and embedded in parafﬁn. Sections were stained with H&E
(hematoxylin-eosin) according to standard protocols. For histologi-
cal morphometry, colonic tissues were embedded in parafﬁn, and
cut into 5 mm of sections and stained with hematoxylin and eosin.
Histopathological grading system was used in a blinded manner:
Grade 0: histological ﬁndings identical to normal mice; Grade 1:
mild mucosal and/or submucosal inﬂammatory inﬁltrate and
edema, punctuate mucosal erosions often associated with capillary
proliferation, muscularis mucosae intact; Grade 2: 50% of the spec-
imen display Grade 1 changes; Grade 3: prominent inﬂammatory
inﬁltrate and edema frequently with deeper areas of ulceration
extending through the muscularis mucosa into the submucosa, rare
inﬂammatory cells invading the muscularis propria but without
muscle necrosis; Grade 4: 50% of the specimen display Grade 3
changes; Grade 5: extensive ulceration with coagulative necrosis
bordered underneath by numerous neutrophils and lesser numbers
of mononuclear cells, necrosis extends deeply into the muscularis
mucosae; Grade 6: 50% of the specimen display Grade 5 changes.
2.6. Cytokine analysis by ELISA
Total protein of colons frommice in each groupwas extracted by
homogenated with lysis buffer. The homogenate was centrifuged at
12,000 g at 4 C for 15 min. The amount of total extracted protein
was determined by BCA™ protein assay kit (Pierce, Rochford, IL).
The amount of IL-1b, IL-17A and TNF-a in the colon homogenate
was quantiﬁed by ELISA kit (Dakewe, Beijing, China) and normal-
ized to the protein quantity.
2.7. Real-time quantitative PCR
RNA samples were reverse transcribed to cDNA and subjected to
quantitative PCR, which was performed with the BioRad CFX96
Touch™ Real-Time PCR Detection System (BioRad，CA) using iQ™
SYBR® Green Supermix (BioRad，CA), and threshold cycle numbers
were obtained using BioRad CFX Manager software. The program
for ampliﬁcation was 1 cycle of 95 C for 2 min followed by 40
cycles of 95 C for 10 s, 60 C for 30 s, and 95 C for 10 s. The primer
sequences used in this study were as follows: tnf-a forward 50-
CGAGTGACAAGCCTGTAGCCC-3’;
tnf-a reverse 50-GTCTTTGAGATCCATGCCGTTG-3;
il-1b forward 50-CTTCAGGCAGGCAGTATCACTC-3’;
il-1b reverse 50-TGCAGTTGTCTAATGGGAACGT-3’;
il-17A forward 50-TCGAGAAGATGCTGGTGGGT-3’;
il-17A reverse 50-CTCTGTTTAGGCTGCCTGGC-3’;
b-actin forward 50-TGCTGTCCCTGTATGCCTCT-3’;
b-actin reverse 50-TTTGATGTCACGCACGATTT-3’
2.8. Western blot
The protein lysates were separated by 10% SDS-PAGE and subse-
quently electrotransferred onto a polyvinylidene diﬂuoride mem-
brane (Millipore, Bedford, MA). The membranewas blocked with 5%
nonfatmilk for 1 h at room temperature. The blockedmembranewas
incubated with the indicated primary Abs, and then with a horse-
radish peroxidase-conjugated secondary Ab. Protein bands were
visualized using Western blotting detection system according to the
manufacturer's instructions (Cell Signaling Technology, MA).
2.9. Statistical analysis
Results were expressed as mean ± SEM of three independent
experiments and each experiment included triplicate sets. Data
were statistically evaluated by one-way ANOVA followed by
W. Guo et al. / Journal of Pharmacological Sciences 129 (2015) 101e106 103Dunnett's test between control group and multiple dose groups.
The level of signiﬁcance was set at a P value of 0.05.
3. Results
3.1. Fumigaclavine C attenuated DSS-induced experimental colitis
In the present study, a mouse model of DSS-induced experi-
mental colitis was used to evaluate the therapeutic effect of Fumi-
gaclavine C. Mice were challenged with DSS for 7 days thus lead to
inﬂammatory conditions in the colon. Oral intake of DSS induces a
severe illness in mice characterized by a dramatic loss of body
weight, evident rectal bleeding and diarrhea. As shown in Fig. 1A,
compared with normal group, mice in DSS group lose about 20%
bodyweight,whilemice from the30mg/kg FumigaclavineC-treated
group just lose 10 percent. Fumigaclavine C also signiﬁcantly
reduced the DAI, a clinical parameter reﬂecting the severity of
weight loss, rectal bleeding and stool consistency (Fig. 1B). DSS
typically causes colonic shortening while such change was also
improved by 10 and 30mg/kg of a Fumigaclavine C and 20mg/kg of
CsA (Fig.1C andD). Histological analysis showeddistortion of crypts,
loss of goblet cells, inﬁltration of mononuclear cells, and severe
mucosal damage in the colon specimens of colitismice (Fig. 2A). The
results of standard pathological examination in mice showedmuch
improvement in pathological changes in mice treated with 30 mg/
kg of Fumigaclavine C and 20 mg/kg of CsA (Fig. 2B).
3.2. Fumigaclavine C inhibited inﬂammatory cytokines expression
in colons of mice with DSS-induced colitis
To determine the effect of Fumigaclavine C on cytokine pro-
duction in mice with DSS-induced colitis, cytokine expression atFig. 1. Fumigaclavine C treatment improved DSS-induced colitis in mice. (AeD) Mice were
another 3 days before sacriﬁced. Fumigaclavine C was given via i.g. from day 1 to day 11. (A
(DAI) was calculated. (C) Macroscopic appearances and (D) the length of colons from each g
(A) and (B), *P < 0.05, **P < 0.01 vs. DSS-treated alone group at the same day. In (D), **P <both mRNA and protein levels in colons were measured in parallel
following induction of colitis. Total RNA of colons were extracted
and analyzed for cytokine mRNA expression using quantitative RT-
PCRmethod. As shown in Fig. 3, the mRNA expressions of TNF-a, IL-
1b, and IL-17A were remarkably increased after DSS challenge.
Fumigaclavine C signiﬁcantly inhibited the elevated expression of
these cytokines after DSS challenge (Fig. 3A). Moreover, we
analyzed the cytokine levels in colonic homogenated protein from
each group via ELISA analysis. Administration of Fumigaclavine C to
mice also signiﬁcantly down-regulated the inﬂammatory cytokines
at protein level (Fig. 3B).
3.3. Fumigaclavine C reduced DSS-induced activation of NF-kB,
STAT3 and STAT1 signaling
Activations of NF-kB, STAT3 and STAT1 all play essential roles in
transcriptional induction of various genes involved in inﬂamma-
tion, such as TNF-a, IL-1b, IFN-g and IL-17A (12). As shown in Fig. 4,
DSS treatment caused different levels of phosphorylations of p65,
STAT3 and STAT1 in the injured colons from mice. Both Fumiga-
clavine C and CsA treatment markedly reduced the phosphoryla-
tions of p65, STAT3 and STAT1.
3.4. Fumigaclavine C reduced cleaved caspase-1 expression of
peritoneal macrophages in DSS-induced colitis mice
To further investigate the mechanism of protection from colitis
by Fumigaclavine C, we examined the regulation of caspase-1
activation in murine peritoneal macrophages in vivo from each
group. We observed that expression of activated caspase-1 (cas-
pase-1 p10) was signiﬁcantly elevated in macrophages from
vehicle-treated DSS mice. In contrast, little cleaved caspase-1given 2.5% DSS in drinking water for 7 days, then mice were provided with water for
) Body weight loss of each group during the disease process. (B) Disease activity index
roup of mice were measured. Data are presented as means ± SEM (n ¼ 6 per group). In
0.01 vs. DSS-treated alone group.
Fig. 2. Fumigaclavine C treatment prevented DSS-induced colon damage in mice. (A) Serial sections of colon tissues were stained with H&E. (B) Histopathological scores of each
group were determined. Data are presented as means ± SEM (n ¼ 6 per group). *P < 0.05, **P < 0.01 vs. DSS-treated alone group.
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treated colonic samples (Fig. 5A).
3.5. Fumigaclavine C inhibited the activation of NLRP3
inﬂammasome in vitro
Caspase-1 is an enzyme that responsible for IL-1b maturation.
IL-1b was processed as an inactive cytoplasmic precursor (pro-IL-
1b) which has to be cleaved by to produce the mature active
form. Evidence indicates that a complex-named NLRP3 inﬂam-
masome (contain NLRP3, ASC and pro-caspase-1) are responsible
for the activation of caspase-1 maturation (caspase-1 p10 and
p20) (13). In order to verify the in vivo results that caspase-1
activation was suppressed by Fumigaclavine C, we build up a
cell model by using LPS and ATP which mimics the process ofFig. 3. Fumigaclavine C suppressed proinﬂammatory cytokine production in colon tissues fro
a, IL-1b and IL-17A in colonic tissues were determined by real-time PCR. (B) Protein levels of
ELISA. Data are presented as means ± SEM (n ¼ 6). *P < 0.05, **P < 0.01 vs. DSS-treated alNLRP3 inﬂammasome activation. As shown in Fig. 5C, Fumiga-
clavine C exhibited a concentration-dependent inhibition of IL-1b
secretion from LPS-treated human monocytic THP-1 cells by the
ELISA assay without affecting the survival of macrophages (data
not shown). Consistent with the results we got in the animal
model, our results showed that activation of caspase-1 (as indi-
cated by the presence of the cleaved form p10 and enzyme ac-
tivity) was also signiﬁcantly inhibited by Fumigaclavine C (Fig. 5B
and D).
4. Discussion
Generally, ulcerative colitis is treated as an autoimmune disease.
Treatments including anti-inﬂammatory drugs, immunosuppres-
sant, and biological therapy targeting speciﬁc components of them DSS-colitis mice. (A) The mRNA expressions of inﬂammation-related cytokines TNF-
cytokines including TNF-a, IL-1b and IL-17A in colonic homogenate were determined by
one group.
Fig. 4. Fumigaclavine C decreased activations of inﬂammatory signaling pathways in colon tissues from DSS-colitis mice. (A) Colonic homogenate from each group of mice were
subjected to Western blot. (B) Phosphorylations of p65, STAT1 and STAT3 were normalized to ACTIN. Data are presented as means ± SEM. *P < 0.05, **P < 0.01 vs. DSS-treated group.
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symptoms. However, they also have potential side effects including
steroid dependence (14) or serious infections (15). Therefore, new
therapeutic strategy and candidates for ulcerative colitis need to be
developed. We report herein that reducing IL-1b release from
macrophages via NLRP3 inﬂammasome inhibition by usingFig. 5. Fumigaclavine C inhibited NLRP3 inﬂammasome activation in vivo and in vitro. (A) Pe
treated colitis mice (30 mg/kg) at day 7. Caspase-1 activation in peritoneal macrophages wa
(12.5, 25, 50 mM) for 1 h, following by 1 h incubation of 5 mM ATP. Protein levels of pro-caspa
IL-1b in the supernatant was analyzed by ELISA (C). Caspase-1 activity was measured (D). Da
group.Fumigaclavine C protects mice against DSS-induced colitis which
suggest target NLRP3 inﬂammasome for ulcerative colitis therapy.
The NLRP3 inﬂammasome is multi-protein complex which
recognize microbial and danger components and serve as a plat-
form for caspase-1 activation and pro-inﬂammatory cytokine IL-1b
maturation (16). NLRP3 inﬂammasome is increasingly beingritoneal macrophages were isolated from normal, vehicle-treated and Fumigaclavine C-
s examined by western blot. (B) LPS-primed THP-1 cells were treated with Asiatic acid
se-1, cleaved caspase-1, ASC and NLRP3 were determined byWestern blot (B). Released
ta are presented as means ± SEM (n ¼ 6 per group). *P < 0.05, **P < 0.01 vs. DSS-treated
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fectious and metabolic diseases. NLRP3 inﬂammasome activation
has a crucial role in host defense against infection while excessive
activation will lead to various auto-inﬂammatory conditions (17).
Still the role of inﬂammasome in colitis is controversy. On one
hand, work by Zaki et al. showed that the NLRP3 inﬂammasome
protected against loss of epithelial integrity and mortality during
experimental colitis (18). On the other hand, On the other hand,
Bauer et al. believed that colitis induced in mice with DSS was
mediated by the NLRP3 inﬂammasome (19). Furthermore, IL-18
neutralization (20,21) or chemical CASP1 inhibitor (22,23) effec-
tively reduced severity in murine colitis. Therefore, inhibition of
CASP1-mediated IL-1b secretion may serve as a useful therapeutic
option for patients with IBD (24,25). Thus target for NLRP3
inﬂammasome complex may be a novel therapy option for patients
with inﬂammatory related diseases.
In this study, we demonstrated that Fumigaclavine C attenuated
the severity of DSS-induced colitis in mice by inhibited NLRP3
inﬂammasome activation. Generally, intragastric administration of
Fumigaclavine C at the dose of 3e30 mg/kg signiﬁcantly recovered
the decrease in body weights, and the diarrhea in colitis mice was
also notably alleviated. Meanwhile, Fumigaclavine C administration
markedly prevented the inﬂammatory damage of colons and the
activation of caspase-1 in peritoneal macrophage cells. These
ﬁndings showed the beneﬁcial effect of Fumigaclavine C on DSS-
induced colitis.
It is known that IL-1b is a proinﬂammatory cytokine mainly
produced by activated macrophages, and it is likely to be essential
in the early phase of the inﬂammatory cascade leading to the
inﬂamed colon. In colitis patients, high levels of the IL-1b are
detected and correlated with the severity of inﬂammation (26).
Moreover, IL-1b modulates the functions of dendritic cells, mac-
rophages, neutrophils, as well as the differentiation of Th17 cells
(27,28). IL-1b is translated as an inactive 31-kDa precursor (pro-IL-
1b) after toll like receptor stimulation (signaling I), and this pre-
cursor is cleaved to its activated 17-kDa form by the NLRP3
inﬂammasome-activated caspase-1. And mechanism study has
proved that NLRP3/ASC/caspase-1-mediated maturation of IL-1b is
essential for experimental colitis induced by (19). Our vivo exper-
iments here showed that treatment with Fumigaclavine C signiﬁ-
cantly reduced prevented the activation of caspase-1 in peritoneal
macrophage cells of mice with DSS-induced colitis. Meanwhile, the
in vitro study suggested that Fumigaclavine C could inhibit NLRP3
activation thus suppressing the activation of caspase-1. We hy-
pothesized that the beneﬁcial effect of Fumigaclavine C on DSS-
induced colitis might be attributed to its inhibition of inﬂamma-
some activation. Still the detail mechanism for how Fumigaclavine
C works on the NLRP3 inﬂammasome activation need to be
explored in the further study.
In conclusion, our work explored a novel therapeutic strategy
for ulcerative colitis by targeting NLRP3 inﬂammasome with
Fumigaclavine C. Administration of Fumigaclavine C signiﬁcantly
attenuated DSS-induced experimental colitis in mice. The mecha-
nism of Fumigaclavine C's action involved inhibition of NLRP3-
caspase-1-IL-1b cascade in macrophages.
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